← Leaderboards
Jonathan E Golub
Johns Hopkins University
$18,054,199
Attributed
$21,870,521
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,870,521 · 11
By mechanism
R01$16,373,232 · 6
U01$2,653,805 · 1
P30$1,614,950 · 2
U2R$664,570 · 1
K01$563,964 · 1
Top collaborators
- Neil A Martinson6 shared
- Akshay Nitin Gupte5 shared
- Vidya Mave5 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Diane M Becker$10,589,971
- Ryan Patrick Westergaard$11,808,719
- Gary S Wand$18,956,510
- Mary E McCaul$21,975,059
- Akshay Nitin Gupte$2,395,374
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisProgramsCost EffectivenessClinicHigh RiskIncidenceEnsureResourcesCostScreeningScale UpGuidelinesMultidisciplinaryRandomizedBrazilPreventPrevalenceEpidemicPrimary OutcomeBasePersonsAdherenceCost EffectiveBehavioral
Grant awards (48)
Developmental Core$750,469
P30 · FY2025 · AI · contact PI
TB Aftermath$588,454
R01 · FY2025 · AI · contact PI
TB PuRe : Pulmonary rehabilitation to reduce post-tuberculosis morbidity$430,078
R01 · FY2025 · AI · contact PI
Evaluating smoking cessation interventions for PWH in South Africa: Efficacy, implementation, and cost-effectiveness.$371,257
U01 · FY2025 · CA · contact PI
Evaluating smoking cessation interventions for PWH in South Africa: Efficacy, implementation, and cost-effectiveness.$363,472
U01 · FY2025 · CA · contact PI
TB PuRe : Pulmonary rehabilitation to reduce post-tuberculosis morbidity$94,312
R01 · FY2025 · AI · contact PI
TB PuRe : Pulmonary rehabilitation to reduce post-tuberculosis morbidity$47,029
R01 · FY2025 · AI · contact PI
TB Aftermath$595,527
R01 · FY2024 · AI · contact PI
TB PuRe : Pulmonary rehabilitation to reduce post-tuberculosis morbidity$587,913
R01 · FY2024 · AI · contact PI
Evaluating smoking cessation interventions for PWH in South Africa: Efficacy, implementation, and cost-effectiveness.$465,107
U01 · FY2024 · CA · contact PI
Developmental Core$291,605
P30 · FY2024 · AI · contact PI
TB PuRe : Pulmonary rehabilitation to reduce post-tuberculosis morbidity$682,368
R01 · FY2023 · AI · contact PI
Developmental Core$287,779
P30 · FY2023 · AI · contact PI
Evaluating smoking cessation interventions for PWH in South Africa: Efficacy, implementation, and cost-effectiveness.$167,600
U01 · FY2023 · CA · contact PI
TB Aftermath$625,680
R01 · FY2022 · AI · contact PI
Evaluating smoking cessation interventions for PWH in South Africa: Efficacy, implementation, and cost-effectiveness.$612,893
U01 · FY2022 · CA · contact PI
PREVINE-TB: PRevent: EValuating the implementation of NEw strategies for preventive TB among people living with HIV in Brazil$571,907
R01 · FY2022 · AI · contact PI
Developmental Core$285,097
P30 · FY2022 · AI · contact PI
Evaluating smoking cessation interventions for PWH in South Africa: Efficacy, implementation, and cost-effectiveness.$673,476
U01 · FY2021 · CA · contact PI
TB Aftermath$631,996
R01 · FY2021 · AI · contact PI
PREVINE-TB: PRevent: EValuating the implementation of NEw strategies for preventive TB among people living with HIV in Brazil$569,023
R01 · FY2021 · AI · contact PI
TB Aftermath$695,483
R01 · FY2020 · AI · contact PI
PREVINE-TB: PRevent: EValuating the implementation of NEw strategies for preventive TB among people living with HIV in Brazil$574,538
R01 · FY2020 · AI · contact PI
PREVINE-TB: PRevent: EValuating the implementation of NEw strategies for preventive TB among people living with HIV in Brazil$574,554
R01 · FY2019 · AI · contact PI
PREVINE-TB: PRevent: EValuating the implementation of NEw strategies for preventive TB among people living with HIV in Brazil$669,384
R01 · FY2018 · AI · contact PI
The Impact of Diabetes on TB treatment outcomes$626,943
R01 · FY2017 · AI · contact PI
Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in Brazil$562,393
R01 · FY2017 · AI · contact PI
Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in Brazil$765,732
R01 · FY2016 · AI · contact PI
The Impact of Diabetes on TB treatment outcomes$588,329
R01 · FY2016 · AI · contact PI
The Impact of Diabetes on TB treatment outcomes$581,164
R01 · FY2015 · AI · contact PI
Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in Brazil$567,810
R01 · FY2015 · AI · contact PI
The Impact of Diabetes on TB treatment outcomes$592,090
R01 · FY2014 · AI · contact PI
Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in Brazil$572,117
R01 · FY2014 · AI · contact PI
A Smoking Cessation Trial in HIV-infected patients in South Africa$486,997
R01 · FY2014 · DA · contact PI
Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in Brazil$339,429
R01 · FY2014 · AI · contact PI
Innovative Approaches for TB Control in Brazil$223,033
U2R · FY2014 · TW · contact PI
Quantiferon Gold Test for Detecting TB Infection in HIV/AIDS Patients in Brazil$600,421
R01 · FY2013 · AI · contact PI
The Impact of Diabetes on TB treatment outcomes$591,808
R01 · FY2013 · AI · contact PI
A Smoking Cessation Trial in HIV-infected patients in South Africa$517,912
R01 · FY2013 · DA · contact PI
Innovative Approaches for TB Control in Brazil$215,108
U2R · FY2013 · TW · contact PI
A Smoking Cessation Trial in HIV-infected patients in South Africa$529,176
R01 · FY2012 · DA · contact PI
Innovative Approaches for TB Control in Brazil$226,429
U2R · FY2012 · TW · contact PI
A Smoking Cessation Trial in HIV-infected patients in South Africa$512,665
R01 · FY2011 · DA · contact PI
Epidemiologic Strategies for Tuberculosis Control$117,938
K01 · FY2009 · AI · contact PI
Epidemiologic Strategies for Tuberculosis Control$115,289
K01 · FY2008 · AI · contact PI
Epidemiologic Strategies for Tuberculosis Control$112,717
K01 · FY2007 · AI · contact PI
Epidemiologic Strategies for Tuberculosis Control$110,222
K01 · FY2006 · AI · contact PI
Epidemiologic Strategies for Tuberculosis Control$107,798
K01 · FY2005 · AI